{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"5.4","upperLimit":"65.9","value":"28.6"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"7"}],"units":"Participants"}],"description":"ECOG Myeloma Response Criteria that follows the standard European Group for Blood and Bone Marrow Transplant criteria was used to evaluate patient response and progression. Patients who have complete disappearance of an M-protein and no evidence of myeloma in the bone marrow are considered to have complete response. 7 eligible and treated patients were included in the analysis.","dispersionType":"90% Confidence Interval","groups":[{"description":"Reinduction treatment: PS-341 1.3 mg/m2 IV push days 1, 4, 8, and 11. As per the PS-341 package insert, there should be at least 72 hours between each PS-341 dose","id":"OG000","title":"PS-341"}],"paramType":"NUMBER","populationDescription":"7 eligible and treated patients were included in the analysis.","reportingStatus":"POSTED","timeFrame":"participants were evaluated prior to each cycle, up to 23 cycles with a median number of 3 cycles. 1 cycle=21 days","title":"Response Rate on Reinduction","type":"SECONDARY","unitOfMeasure":"percentage of participants"}